Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALB | P02768 | 11/20 | 0.56 |
| ▸ | IL2 | P60568 | 11/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147706 | 0.84 | HRH4 (0.56) | GAAALBIL2HDAC3HDAC1 | |
| SCHEMBL15511675 | 0.82 | FLT3 (0.57) | KDM4EALDH1A1GAAMAPK1ALB | |
| SCHEMBL3417091 | 0.82 | FLT3 (0.60) | KDM4EALDH1A1GAAMAPK1ALB | |
| SCHEMBL30189206 | 0.82 | FLT3 (0.60) | KDM4EALDH1A1GAAMAPK1ALB | |
| SCHEMBL11717486 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1GAAMAPK1FLT3 | |
| SCHEMBL31392771 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1GAAMAPK1ALB | |
| SCHEMBL24019693 | 0.81 | ALB (0.60) | ALBIL2FLT3HRH4TNF | |
| SCHEMBL16234660 | 0.79 | HRH4 (0.59) | KDM4EALDH1A1GAAMAPK1ALB | |
| SCHEMBL19476401 | 0.79 | FLT3 (0.51) | ALBIL2HDAC3HDAC1FLT3 | |
| SCHEMBL24446999 | 0.78 | ALB (0.56) | GAAALBIL2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350315-A | 2- (1H-indole-2-yl) -1,3, 4-oxadiazole derivatives, and preparation method and application thereof | 南开大学 | 2025-01-24 | — | — | CN | claimed |
| CN-119350315-A | 2- (1H-indole-2-yl) -1,3, 4-oxadiazole derivatives, and preparation method and application thereof | 南开大学 | 2025-01-24 | — | — | CN | disclosed |
| EP-2753618-B1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| WO-2013034047-A1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, GTF3C5, EIF5B | KDM4E 2235/4885ALDH1A1 341/4885GAA 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.